Thrombosis and Hemostasis Research

Thrombosis is a crucial hemostatic process for maintaining blood volume (hemostasis) following injury, yet aberrant thrombosis can trigger pathological conditions including myocardial infarction and stroke. Therefore the initiation of thrombosis is tightly controlled under physiological conditions.

Products for Thrombosis and Hemostasis Research - Page 19

Cat.No. Product Name Information/Activity
BCC7624 UTPγS trisodium salt 1266569-94-1
BCC6004 AR-C 66096 tetrasodium salt Potent and selective P2Y<sub>12</sub> antagonist
BCC2497 Clopidogrel Clopidogrel hydrogen sulfate is an antiplatelet agent which works by blocking platelets from sticking together and prevents them from forming harmful clots.
BCC5685 MRS 2179 tetrasodium salt 1454889-37-2
BCC5880 MRS 2279 367909-40-8
BCC5881 MRS 2500 tetraammonium salt 630103-23-0
BCC4976 MRS 2578 MRS 2578 is a selective and potent P2Y6 receptor antagonist with IC50s of 37 nM (human) and 98 nM (rat). MRS 2578 exhibits insignificant activity at P2Y1, P2Y2, P2Y4, and P2Y11 receptors.
BCC7367 NF 157 NF157 is a highly selective nanomolar P2Y11 antagonist with a pKi of 7.35. The IC50s are 463 nM, 1811 µM, 170 µM for P2Y11 (Ki=44.3 nM), P2Y1 (Ki=187 µM), P2Y2 (Ki=28.9 µM), respectively. NF157, significantly reduces expression of metalloproteinase (MMP)-3, MMP-13, can be used in the treatment of osteoarthritis (OA).
BCC7785 NF 340 202982-98-7
BCC6725 PPADS tetrasodium salt PPADS tetrasodiuma is a non-selective P2X receptor antagonist. PPADS tetrasodiuma blocks recombinant P2X1, -2, -3, -5 with IC50s ranging from 1 to 2.6 μM. PPADS tetrasodiuma blocks native P2Y2-like (IC50~0.9 mM) and recombinant P2Y4 (IC50~15 mM) receptors. PPADS tetrasodiuma is an inhibitor of the reverse mode of the Na/Ca²⁺exchanger in guinea pig airway smooth muscle.

Thrombosis and Hemostasis Research

Thrombosis and Hemostasis Research Products Targets

Products for Thrombosis and Hemostasis Research - Page 19